Compare CRC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRC | BLLN |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | N/A | 2025 |
| Metric | CRC | BLLN |
|---|---|---|
| Price | $51.16 | $86.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $61.88 | ★ $137.83 |
| AVG Volume (30 Days) | ★ 872.7K | 240.3K |
| Earning Date | 03-02-2026 | 12-09-2025 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.29 | N/A |
| Revenue | ★ $3,505,000,000.00 | $254,136,000.00 |
| Revenue This Year | $20.78 | $98.01 |
| Revenue Next Year | N/A | $35.84 |
| P/E Ratio | $11.81 | ★ N/A |
| Revenue Growth | 34.91 | ★ 254.30 |
| 52 Week Low | $30.97 | $80.00 |
| 52 Week High | $58.41 | $138.70 |
| Indicator | CRC | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 65.84 | 45.29 |
| Support Level | $48.25 | $80.00 |
| Resistance Level | $51.18 | $94.16 |
| Average True Range (ATR) | 1.64 | 6.79 |
| MACD | 0.48 | -0.05 |
| Stochastic Oscillator | 85.94 | 30.25 |
California Resources Corp is an independent oil and natural gas exploration and production company operating properties exclusively within California. It provides affordable and reliable energy in a safe and responsible manner, to support and enhance the quality of life of Californians and the local communities in which the company operates. It has some of the lowest carbon intensity production in the United States and is focused on maximizing the value of its land, mineral, and technical resources for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.